Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials-Reference-Cited by-同舟云学术

Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials

Published:2019-04 Issue: Volume:150 Page:120-125
ISSN:0954-6111
Container-title:Respiratory Medicine
language:en
Short-container-title:Respiratory Medicine

Author:

Wuyts Wim,Antin-Ozerkis Danielle,Huggins J. Terrill,LaCamera Peter P.,Spagnolo Paolo,Vašáková Martina,Wijsenbeek Marlies S.,Polman Boris,Kirchgaessler Klaus-Uwe,Scholand Mary Beth

Funder

InterMune

Boehringer Ingelheim

Fibrogen

Genentech

Promedior

Celgene

Gilead

Roche/Genentech

InterMune, Inc.

INSPIRE

ASCEND

CAPACITY

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Roche/Genentech.

Genentech, Inc

Health Interactions, Inc.

F. Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference25 articles.

1. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am. J. Respir. Crit. Care Med.,2011

2. Classification and natural history of the idiopathic interstitial pneumonias;Kim;Proc. Am. Thorac. Soc.,2006

3. Idiopathic pulmonary fibrosis: diagnosis, epidemiology and natural history;Sgalla;Respirology,2016

4. Clinical course and prediction of survival in idiopathic pulmonary fibrosis;Ley;Am. J. Respir. Crit. Care Med.,2011

5. Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis;Oda;Respir. Res.,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing domain adaptation in adverse drug event extraction on real-world breast cancer records;International Journal of Medical Informatics;2024-11

2. Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants;American Journal of Gastroenterology;2022-09-30

3. The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials;PLOS ONE;2021-05-14

4. Cardiovascular safety of the tyrosine kinase inhibitor nintedanib;British Journal of Clinical Pharmacology;2021-03-08